Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chairman, President and CEO

Chief Technical Officer

Chief Financial Officer

Chief Scientific Officer

Chief Medical Officer

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines o...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-10-27	Premium	bought	Premium	Premium	Premium	Chairman, President and CEO
2023-10-27	Premium	bought	Premium	Premium	Premium	-
2023-06-14	Premium	bought	Premium	Premium	Premium	Chief Technical Officer
2023-05-30	Premium	bought	Premium	Premium	Premium	-
2023-05-17	Premium	bought	Premium	Premium	Premium	-
2023-05-15	Premium	bought	Premium	Premium	Premium	Chairman, President and CEO
2023-03-15	Premium	bought	Premium	Premium	Premium	Chairman, President and CEO
2023-02-06	Premium	sold (taxes)	Premium	Premium	Premium	-
2023-02-06	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-01-07	Premium	back to issuer	Premium	Premium	Premium	Chief Scientific Officer
2023-01-07	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-01-07	Premium	back to issuer	Premium	Premium	Premium	Chief Medical Officer
2023-01-07	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-01-07	Premium	acquired	Premium	Premium	Premium	Chief Technical Officer
2023-01-07	Premium	back to issuer	Premium	Premium	Premium	Chief Technical Officer
2023-01-07	Premium	back to issuer	Premium	Premium	Premium	Chairman, President and CEO
2023-01-07	Premium	acquired	Premium	Premium	Premium	Chairman, President and CEO
2022-12-14	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2022-12-14	Premium	acquired	Premium	Premium	Premium	-
2022-12-14	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2022-12-14	Premium	acquired	Premium	Premium	Premium	Chairman, President and CEO
2022-12-14	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2022-12-14	Premium	acquired	Premium	Premium	Premium	-
2022-12-14	Premium	acquired	Premium	Premium	Premium	-
2022-12-14	Premium	acquired	Premium	Premium	Premium	Chief Technical Officer

SONN - Sonnet BioTherapeutics Holdings Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for SONN